Search research articles
Contact Us
Filters
Showing results (501-510 of 578) with videos related to
Page
of 58
Sort By:
The Lancet. Oncology
|
July 28, 2022
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, et al.
Epigenetics
|
September 28, 2013
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
Ivana Türbachova, Tim Schwachula, Ines Vasconcelos, et al.
The Lancet. Oncology
|
July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Cell Reports. Medicine
|
December 20, 2023
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Christian Pozzorini, Gregoire Andre, Tommaso Coletta, et al.
Cancers
|
July 14, 2023
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Eva-Maria Willing, Claudia Vollbrecht, Christine Vössing, et al.
Genome Medicine
|
October 27, 2015
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Andrew E Teschendorff, Shih-Han Lee, Allison Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2023
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
Ignace Vergote, Els Van Nieuwenhuysen, Roisin E O'Cearbhaill, et al.
Gynecologic Oncology
|
April 18, 2026
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
Els Van Nieuwenhuysen, Ignace Vergote, Leslie M Randall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2020
Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial
David Cibula, Roman Kocian, Andrea Plaikner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 27, 2023
Gestational choriocarcinoma
Giorgio Bogani, Isabelle Ray-Coquard, David Mutch, et al.
Page
of 58
Search research articles
Search
Showing results (501-510 of 578) with videos related to
Sort By:
Page
of 58
The Lancet. Oncology
|
July 28, 2022
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, et al.
Epigenetics
|
September 28, 2013
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
Ivana Türbachova, Tim Schwachula, Ines Vasconcelos, et al.
The Lancet. Oncology
|
July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Cell Reports. Medicine
|
December 20, 2023
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Christian Pozzorini, Gregoire Andre, Tommaso Coletta, et al.
Cancers
|
July 14, 2023
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Eva-Maria Willing, Claudia Vollbrecht, Christine Vössing, et al.
Genome Medicine
|
October 27, 2015
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Andrew E Teschendorff, Shih-Han Lee, Allison Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2023
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
Ignace Vergote, Els Van Nieuwenhuysen, Roisin E O'Cearbhaill, et al.
Gynecologic Oncology
|
April 18, 2026
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
Els Van Nieuwenhuysen, Ignace Vergote, Leslie M Randall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2020
Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial
David Cibula, Roman Kocian, Andrea Plaikner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 27, 2023
Gestational choriocarcinoma
Giorgio Bogani, Isabelle Ray-Coquard, David Mutch, et al.
Page
of 58